Mesenchymal stem cell therapies for COVID-19: Current status and mechanism of action

Wang, 2020, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA, 323, 1061, 10.1001/jama.2020.1585 Metcalfe, 2020, Mesenchymal stem cells and management of COVID-19 pneumonia, Med. Drug Discov., 5, 100019, 10.1016/j.medidd.2020.100019 Zhou, 2020, COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression, J. Antimicrob. Chemother., 75, 1667, 10.1093/jac/dkaa114 Murphy, 2013, Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine, Exp. Mol. Med., 45, e54, 10.1038/emm.2013.94 Wang, 2012, Clinical applications of mesenchymal stem cells, J. Hematol. Oncol., 5, 19, 10.1186/1756-8722-5-19 Leng, 2020, Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia, Aging Dis., 11, 216, 10.14336/AD.2020.0228 Sadeghi, 2020, The immunomodulatory effects of mesenchymal stem cells on long term pulmonary complications in an animal model exposed to a sulfur mustard analog, Int. Immunopharmacol., 80, 10.1016/j.intimp.2019.105879 Li, 2020, Molecular immune pathogenesis and diagnosis of COVID-19, J. Pharm. Anal, 10, 102, 10.1016/j.jpha.2020.03.001 Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 Atluri, 2020, Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use, Pain Phys, 23, E71 Xu, 2020, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir. Med., 8, 420, 10.1016/S2213-2600(20)30076-X Blackwell, 2009, HLA and infectious diseases, Clin. Microbiol. Rev., 22, 370, 10.1128/CMR.00048-08 Crux, 2017, Human leukocyte antigen (HLA) and immune regulation: how do classical and non-classical HLA alleles modulate immune response to human immunodeficiency virus and hepatitis C virus infections?, Front. Immunol., 8, 832, 10.3389/fimmu.2017.00832 Luckey, 2019, Immunity to influenza is dependent on MHC II polymorphism: study with 2 HLA transgenic strains, Sci. Rep., 9, 1, 10.1038/s41598-019-55503-1 Huang, 1973, Lymphopenia and multiple viral infections, JAMA, 225, 1120, 10.1001/jama.1973.03220370058023 Jiang, 2019, Nonviral infection-related lymphocytopenia for the prediction of adult sepsis and its persistence indicates a higher mortality, Medicine, 98, 10.1097/MD.0000000000016535 Hatipoğlu, 2011, Laboratory findings in the diagnosis of infectious diseases, Jopp Derg, 3, 5 Boonnak, 2014, Lymphopenia associated with highly virulent H5N1 virus infection due to plasmacytoid dendritic cell-mediated apoptosis of T cells, J. Immunol., 192, 5906, 10.4049/jimmunol.1302992 Tan, 2020, Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study, Sign. Transduct. Target. Ther, 5, 1 Chan, 2008, Mechanisms of lymphocyte loss in SARS coronavirus infection, Hong Kong Med. J. = Xianggang yi xue za zhi, 14, 21 Li, 2003, SARS-coronavirus replicates in mononuclear cells of peripheral blood (PBMCs) from SARS patients, J. Clin. Virol., 28, 239, 10.1016/S1386-6532(03)00195-1 Kahan, 2015, T cell exhaustion during persistent viral infections, Virology, 479, 180, 10.1016/j.virol.2014.12.033 Diao, 2020, Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19), Front. Immunol., 11, 827, 10.3389/fimmu.2020.00827 Zheng, 2020, Functional exhaustion of antiviral lymphocytes in COVID-19 patients, Cell. Mol. Immunol., 17, 533, 10.1038/s41423-020-0402-2 Vabret, 2020, Immunology of COVID-19: current state of the science, Immunity, 52, 910, 10.1016/j.immuni.2020.05.002 Ju, 2020, Potent human neutralizing antibodies elicited by SARS-CoV-2 infection, BioRxiv Wu, 2020 Takada, 2003, Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications, Rev. Med. Virol., 13, 387, 10.1002/rmv.405 Ubol, 2010, How innate immune mechanisms contribute to antibody-enhanced viral infections, Clin. Vaccine Immunol., 17, 1829, 10.1128/CVI.00316-10 Zhang, 2020, Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19, Front. Mol. Biosci., 7, 10.3389/fmolb.2020.00157 Zhao, 2020, Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019, Clin. Infect. Dis., 10.1093/cid/ciaa344 2017 Chen, 2020, Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies, Zhonghua Shao Shang Za Zhi = Zhonghua Shaoshang Zazhi = Chin. J. Burns, 36, E005 Wang, 2008, The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome, Am. J. Emerg. Med., 26, 711, 10.1016/j.ajem.2007.10.031 Shimabukuro-Vornhagen, 2018, Cytokine release syndrome, J. Immunother. Cancer, 6, 56, 10.1186/s40425-018-0343-9 Guo, 2020, The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status, Mil. Med. Res, 7, 1 Norkaew, 2018, Body condition and adrenal glucocorticoid activity affects metabolic marker and lipid profiles in captive female elephants in Thailand, PLoS One, 13, 10.1371/journal.pone.0204965 Mehta, 2020, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet (London, England), 395, 1033, 10.1016/S0140-6736(20)30628-0 Sanders, 2020, Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review, Jama, 323, 1824 Horby, 2020, Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report, MedRxiv Henter, 2006, Cytotoxic therapy for severe avian influenza A (H5N1) infection, Lancet, 367, 870, 10.1016/S0140-6736(06)68232-9 Maschalidi, 2016, Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice, Blood, 128, 60, 10.1182/blood-2016-02-700013 Bridgeman, 2014, CD 3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy, Clin. Exp. Immunol., 175, 258, 10.1111/cei.12216 Yi, 2020, COVID-19: what has been learned and to be learned about the novel coronavirus disease, Int. J. Biol. Sci., 16, 1753, 10.7150/ijbs.45134 Zhou, 2007, Treatment with convalescent plasma for influenza A (H5N1) infection, N. Engl. J. Med., 357, 1450, 10.1056/NEJMc070359 Cheng, 2005, Use of convalescent plasma therapy in SARS patients in Hong Kong, Eur. J. Clin. Microbiol. Infect. Dis., 24, 44, 10.1007/s10096-004-1271-9 Liu, 2020, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell discovery, 6, 1, 10.1038/s41421-019-0132-8 Hernandez, 2020, Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review, Ann. Intern. Med., 173, 287, 10.7326/M20-2496 Behnke, 2020, MSC based therapies—new perspectives for the injured lung, J. Clin. Med., 9, 682, 10.3390/jcm9030682 Golchin, 2020, Mesenchymal stem cell therapy for COVID-19: present or future, Stem Cell Rev. Rep., 1 Shafiee, 2015, Fetal endothelial and mesenchymal progenitors from the human term placenta: potency and clinical potential, Stem Cells Transl. Med., 4, 419, 10.5966/sctm.2014-0224 Harrell, 2019, Mesenchymal stem cell-based therapy of inflammatory lung diseases: current understanding and future perspectives, Stem Cells Int., 2019, 10.1155/2019/4236973 Krasnodembskaya, 2014, Human mesenchymal stem cells (MSC) modulate alveolar macrophage polarization in vivo and in vitro, Eur. Respir. J., 44 Lee, 2011, Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors, Stem Cells, 29, 913, 10.1002/stem.643 Mei, 2010, Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis, Am. J. Respir. Crit. Care Med., 182, 1047, 10.1164/rccm.201001-0010OC Kode, 2009, Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration, Cytotherapy, 11, 377, 10.1080/14653240903080367 Mei, 2007, Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1, PLoS Med., 4, e269, 10.1371/journal.pmed.0040269 Trounson, 2015, Stem cell therapies in clinical trials: progress and challenges, Cell Stem Cell, 17, 11, 10.1016/j.stem.2015.06.007 Tzouvelekis, 2013, A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis, J. Transl. Med., 11, 171, 10.1186/1479-5876-11-171 Sara, 2020, Cell therapy for lung disease: current status and future prospects, Current Stem Cell Reports, 6, 30, 10.1007/s40778-020-00171-5 Lee, 2009, Potential application of mesenchymal stem cells in acute lung injury, Expert. Opin. Biol. Ther., 9, 1259, 10.1517/14712590903213651 Pittenger, 2019, Mesenchymal stem cell perspective: cell biology to clinical progress, NPJ Regener. Med, 4, 1, 10.1038/s41536-019-0083-6 Lee, 2019, The anti-inflammatory, anti-oxidative, and anti-apoptotic benefits of stem cells in acute ischemic kidney injury, Int. J. Mol. Sci., 20, 3529, 10.3390/ijms20143529 Han, 2019, Genetically modified mesenchymal stem cell therapy for acute respiratory distress syndrome, Stem Cell Res Ther, 10, 386, 10.1186/s13287-019-1518-0 Squillaro, 2016, Clinical trials with mesenchymal stem cells: an update, Cell Transplant., 25, 829, 10.3727/096368915X689622 Chen, 2020, Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment, Engineering, 10.1016/j.eng.2020.02.006 Bernard, 2018, Mesenchymal stem cells reduce hypoxia-induced apoptosis in alveolar epithelial cells by modulating HIF and ROS hypoxic signaling, Am. J. Phys. Lung Cell. Mol. Phys., 314, L360 Han, 2019, Mesenchymal stem cells for regenerative medicine, Cells, 8, 886, 10.3390/cells8080886 DiMarino, 2013, Mesenchymal stem cells in tissue repair, Front. Immunol., 4, 201, 10.3389/fimmu.2013.00201 Shafiee, 2017, Mesenchymal stem/stromal cells enhance engraftment, vasculogenic and pro-angiogenic activities of endothelial colony forming cells in immunocompetent hosts, Sci. Rep., 7, 1, 10.1038/s41598-017-13971-3 Siegel, 2019 Laffey, 2017, Fifty years of research in ARDS. Cell-based therapy for acute respiratory distress syndrome. Biology and potential therapeutic value, Am. J. Respir. Crit. Care Med., 196, 266, 10.1164/rccm.201701-0107CP Matthay, 2010, Therapeutic potential of mesenchymal stem cells for severe acute lung injury, Chest, 138, 965, 10.1378/chest.10-0518 Savukinas, 2016, Concise review: the bystander effect: mesenchymal stem cell-mediated lung repair, Stem Cells, 34, 1437, 10.1002/stem.2357 Al-Anazi, 2015, Mesenchymal stem cells—their antimicrobial effects and their promising future role as novel therapies of infectious complications in high risk patients, Progress in Stem Cell Transplantation, 10.5772/60640 Ai, 2020, Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in eastern China, MedRxiv Matthay, 2015, Therapeutic potential of mesenchymal stromal cells for acute respiratory distress syndrome, Ann. Am. Thorac. Soc., 12, S54, 10.1513/AnnalsATS.201406-254MG Qian, 2016, Exosomal microRNAs derived from umbilical mesenchymal stem cells inhibit hepatitis C virus infection, Stem Cells Transl. Med., 5, 1190, 10.5966/sctm.2015-0348 Li, 2018, Base modifications: regulation of stem cell functions and diseases, Stem Cells Int., 2018, 10.1155/2018/5402384 Baharlooi, 2020, Mesenchymal stem cell-derived exosomes: a promising therapeutic ace card to address autoimmune diseases, Int. J. Stem Cells, 13, 13, 10.15283/ijsc19108 Zheng, 2014, Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study, Respir. Res., 15, 39, 10.1186/1465-9921-15-39 Danchuk, 2011, Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6, Stem Cell Res Ther, 2, 27, 10.1186/scrt68 Iyer, 2010, Effect of bone marrow-derived mesenchymal stem cells on endotoxin-induced oxidation of plasma cysteine and glutathione in mice, Stem Cells Int., 2010, 10.4061/2010/868076 Simonson, 2015, In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome, Stem Cells Transl. Med., 4, 1199, 10.5966/sctm.2015-0021 Krasnodembskaya, 2010, Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37, Stem Cells, 28, 2229, 10.1002/stem.544 Rajarshi, 2020, Combating COVID-19 with mesenchymal stem cell therapy, Biotechnol. Rep, e00467, 10.1016/j.btre.2020.e00467 Fang, 2010, Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1, J. Biol. Chem., 285, 26211, 10.1074/jbc.M110.119917 Hayes, 2012, Clinical review: stem cell therapies for acute lung injury/acute respiratory distress syndrome-hope or hype?, Crit. Care, 16, 1, 10.1186/cc10570 Khoury, 2020, Cell-based therapies for COVID-19: proper clinical investigations are essential, Cytotherapy Khoury, 2020, Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19, Eur. Respir. J., 55, 10.1183/13993003.00858-2020 London, 2020, Against pandemic research exceptionalism, Science, 368, 476, 10.1126/science.abc1731 Gorman, 2020, Repair of acute respiratory distress syndrome by stromal cell administration in COVID-19 (REALIST-COVID-19): a structured summary of a study protocol for a randomised, controlled trial, Trials, 21, 1, 10.1186/s13063-020-04416-w Moll, 2020, MSC therapies for COVID-19: importance of patient coagulopathy, thromboprophylaxis, cell product quality and mode of delivery for treatment safety and efficacy, Front. Immunol., 11, 1091, 10.3389/fimmu.2020.01091 Liang, 2020, Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells, ChinaXiv, 2, v1